High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers

By afschroeder • August 9, 2025

Ennin E, Mallepally N, Ali M, Shojaie L, Dewberry S, Trieu M, Torres ETR, Zhou K, Kahn J, Dodge JL, Dara L. High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers. Liver Int. 2025 Sep;45(9):e70255. doi: 10.1111/liv.70255. PMID: 40778804.

Tags: CTLA‐4, Digestive Diseases, Fellow, ILICI, immune‐related adverse events, immunotherapy, liver injury, PD‐1, Publications

COVID-19 outcomes among individuals with substance use disorders

Chang CE, Knox D, Yu ZD, Shoaf K, Talboys SL, Hashibe M. COVID-19 outcomes among individuals with substance use disorders. Public Health. 2026 Jan 16;252:106156.[...]

The 2025 top 10 list of endoscopy topics in medical publishing: an annual review by the American Society for Gastrointestinal Endoscopy Editorial Board

Martinez M, Dakhoul L, Goenka MK, Gomez V, Hernandez LV, Jensen D, Khaykis I, Lara LF, Tadros M, Villa E, Saltzman JR. The 2025 top[...]

Comprehensive Assessment of Direct and Passive Smoking Across the Pancreatitis Spectrum

Han S, Yadav D, Xu J, Bellin MD, Fisher WE, Fogel EL, Forsmark C, Hart PA, Li L, Pandol SJ, Park WG, Trikudanathan G, Van[...]